Kenvue Inc. (NYSE:KVUE) Stock Position Reduced by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lowered its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 57.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 206,105 shares of the company's stock after selling 280,061 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in Kenvue were worth $4,767,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Kenvue by 12.0% in the 1st quarter. Vanguard Group Inc. now owns 166,789,085 shares of the company's stock valued at $3,579,294,000 after buying an additional 17,908,497 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Kenvue by 23.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company's stock worth $2,887,773,000 after buying an additional 25,238,112 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in Kenvue by 9.6% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 79,863,967 shares of the company's stock worth $1,451,927,000 after acquiring an additional 7,023,047 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Kenvue by 11.1% in the 1st quarter. JPMorgan Chase & Co. now owns 68,319,998 shares of the company's stock worth $1,466,147,000 after purchasing an additional 6,825,611 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Kenvue by 21.0% in the second quarter. Bank of New York Mellon Corp now owns 43,444,085 shares of the company's stock worth $789,813,000 after buying an additional 7,546,362 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on KVUE shares. UBS Group boosted their price target on Kenvue from $20.00 to $22.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 7th. Piper Sandler raised their price objective on Kenvue from $20.00 to $21.00 and gave the stock a "neutral" rating in a research report on Monday, September 23rd. Bank of America raised their target price on Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a research report on Tuesday, October 22nd. JPMorgan Chase & Co. increased their price target on shares of Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. Finally, Royal Bank of Canada downgraded shares of Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 price objective for the company. in a research note on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $22.64.

Kenvue Stock Up 3.1 %

Shares of KVUE stock traded up $0.71 during mid-day trading on Friday, reaching $23.68. 16,635,437 shares of the company were exchanged, compared to its average volume of 16,248,485. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99. The business's 50 day simple moving average is $22.65 and its 200 day simple moving average is $20.53. The company has a market capitalization of $45.35 billion, a P/E ratio of 40.84, a P/E/G ratio of 2.94 and a beta of 1.36. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $23.72.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The company had revenue of $3.90 billion during the quarter, compared to analysts' expectations of $3.92 billion. During the same period in the prior year, the business posted $0.31 EPS. Kenvue's quarterly revenue was down .4% compared to the same quarter last year. Research analysts predict that Kenvue Inc. will post 1.08 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a yield of 3.46%. Kenvue's dividend payout ratio (DPR) is presently 141.38%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.